Sergiy Tsivkach joined Polish Investment and Trade Agency sectoral consultations on pharmaceutical and medical industries to discuss cooperation with Polish businesses in the recovery of exports and the post-war reconstruction. The Embassy of Poland in Ukraine co-hosted the event.
UkraineInvest’s Executive Director presented the investment potential of the Ukrainian pharmaceutical market that demonstrates over 20% profitability growth before Russian aggression.
Ukrainian internal market is fairly evenly distributed among different participants; JSC Farmak (5.25%), Darnytsa pharmaceutical company (4.45%), and the Swiss-based Acino pharmaceutical company (3.6%) are the biggest distributors while every other mainly foreign manufacturer possesses an approximately 3% share. In 2021 the sector of e-commerce in the Ukrainian pharma market was more significant than in other countries around the world.
Promoting prospects for Polish investors in Ukraine, Sergiy Tsivkach mentioned several investment incentives such as a 10-year CIT exemption, import duties exemption for new equipment, free access to infrastructure and engineering facilities built at the expense of the state budget; up to 30% return of capital investment for significant investors (20 million euros).
Sergiy Tsivkach also mentioned 61 industrial parks registered in Ukraine to create favorable conditions for the implementation of investment projects. As a government office, UkraineInvest provides free consultations for businesses, primarily on issues of investment incentives provided for by Ukrainian legislation.
You can read the analytical review of the pharmaceutical industry in Ukraine prepared by our UkraineInvest team below.
Follow us on Facebook, Twitter, LinkedIn, or YouTube.
